Biography for John Carroll
John D. Carroll, Editor-in-Chief
John D. Carroll is a biotech analyst with 36 years of experience in journalism that’s taken him all over the world--and back again. Appointed editor of FierceBiotech in 2003, he has covered everything from city hall in Kansas City, KS, to biotech in London. He contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press and a medley of other publications. He spent six years as editor and then publisher of the Dallas Business Journal, was publisher of Texas Business for a brief stint and early in his career was part of a big team of reporters and editors at the Kansas City Star & Times that investigated the deadly 1981 disaster at a local Hyatt Regency. The newspapers won a 1982 Pulitzer for their collective work. Carroll lives in Vermont and travels frequently. He can be reached at firstname.lastname@example.org. Follow @JohnCFierce on Twitter.
Articles by John Carroll
In biotech, here are the top 10 news stories of the year so far, based on web traffic.
The FDA has slapped down Bristol-Myers Squibb's closely watched hep C drug daclatasvir, handing out a complete response letter for the linchpin drug in its cocktail strategy.
Scientists with the UC Irvine School of Medicine and the Italian Institute of Technology have spotlighted what they call the "very first class" of acid ceramidase inhibitors that could eventually go on to help amp up the effectiveness of chemotherapies.
What makes Woodford such a potent figure is the example he sets in backing global drug development, where even small companies knit together scientific, administrative and support functions from an international cast of players.
While investors have been pouring hundreds of millions of dollars into a virtual Manhattan Project on new immuno-oncology drugs, a startup that sprang out of a lab at New York University's Langone Medical Center has taken the first steps in what it sees as a unique follow-up to the first wave of therapies.
Amgen and AstraZeneca have racked up their third straight Phase III win for brodalumab in plaque psoriasis, beating J&J's Stelara in a head-to-head study. The news comes just two weeks after the pharma partners posted their latest positive results, positioning them for a run at regulators on both sides of the Atlantic.
Five years after the FDA formally rejected J&J's Yondelis (trabectedin) for ovarian cancer, and three years after an aborted effort to get it back on track, the pharma giant has finally made its way back to the agency for another try at an approval--this time as a treatment for soft tissue sarcoma.
Will they or won't they? That question seems to be on quite a few minds these days as the oddsmakers assess the chances of another Pfizer megamerger bid for AstraZeneca after the U.K.'s cooling off period ends on Wednesday.
Johnson & Johnson is following in the footsteps of pioneers like Novartis, Celgene and GlaxoSmithKline, inking a discovery-stage development deal--but turning to the little-known Transposagen Biopharmaceuticals to make its entry.
Polaris Partners, an ambitious venture investor that's been behind a legion of cutting-edge biotech startups, has come up with $450 million for its latest fund. The cash tops the $400 million mark that the VC had outlined in an SEC filing last summer, signaling another success for the year's blossoming class of new biotech venture funds.